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Abstract
Viral homologs of the anti-apoptotic Bcl-2 proteins are highly diverged from their mammalian 
counterparts, yet they perform overlapping functions by binding and inhibiting BH3 motif-
containing proteins. We investigated the BH3 binding properties of the herpesvirus Bcl-2 
homologs KSBcl-2, BHRF1, and M11, as they relate to those of the human Bcl-2 homologs 
Mcl-1, Bfl-1, Bcl-w, Bcl-xL, and Bcl-2. Analysis of the sequence and structure of the BH3 binding 
grooves showed that, despite low sequence identity, M11 has structural similarities to Bcl-xL, 
Bcl-2, and Bcl-w. BHRF1 and KSBcl-2 are more structurally similar to Mcl-1 than to the other 
human proteins. Binding to human BH3-like peptides showed that KSBcl-2 has similar specificity 
to Mcl-1, and BHRF1 has a restricted binding profile; M11 binding preferences are distinct from 
those of Bcl-xL, Bcl-2 and Bcl-w. Because KSBcl-2 and BHRF1 are from human herpesviruses 
associated with malignancies, we screened computationally designed BH3 peptide libraries using 
bacterial surface display to identify selective binders of KSBcl-2 or BHRF1. The resulting 
peptides bound to KSBcl-2 and BHRF1 in preference to Bfl-1, Bcl-w, Bcl-xL, and Bcl-2, but 
showed only modest specificity over Mcl-1. Rational mutagenesis increased specificity against 
Mcl-1, resulting in a peptide with a dissociation constant of 2.9 nM for binding to KSBcl-2 and 
>1000-fold specificity over human Bcl-2 proteins, and a peptide with >70-fold specificity for 
BHRF1. In addition to providing new insights into viral Bcl-2 binding specificity, this study will 
inform future work analyzing the interaction properties of homologous binding domains and 
designing specific protein interaction partners.
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Introduction
Many proteins function by binding selectively to other proteins. Within homologous 
families of protein interaction domains, members can have overlapping yet distinct 
functional specificities that are determined by factors such as expression pattern, subcellular 
localization, turnover, and intrinsic biochemical properties. The Bcl-2 family of proteins 
regulates apoptosis using selective interactions between its pro- and anti-apoptotic members. 
In these regulatory complexes, a helix formed by the BH3 (Bcl-2 homology 3) motif of a 
pro-apoptotic family member binds into a groove on the surface of a globular anti-apoptotic 
receptor. In humans, there are five main anti-apoptotic Bcl-2 family receptor proteins: Bcl-
xL, Bcl-2, Bcl-w, Mcl-1, and Bfl-1. Three classes of pro-apoptotic Bcl-2 family proteins can 
engage these receptors via BH3 docking.1,2 First, multi-Bcl-2 homology motif effector 
proteins Bax and Bak oligomerize in the outer mitochondrial membrane to promote 
apoptosis; binding of anti-apoptotic proteins to the helical BH3 motifs in Bak or Bax inhibits 
this process and can block cell death. Second, pro-apoptotic activator BH3-only proteins 
such as Bid and Bim trigger the oligomerization of Bak and Bax, and this activity is 
suppressed by anti-apoptotic receptors binding to activator BH3 motifs. Finally, pro-
apoptotic BH3-only sensitizer proteins contain BH3 motifs that selectively bind and inhibit 
subsets of anti-apoptotic receptors.3 Thus, sensitizer proteins promote apoptosis in a manner 
that depends on the complement of anti-apoptotic proteins expressed in a particular cell. 
Competitive binding of the three classes of BH3-containing proteins to anti-apoptotic 
proteins is a key mechanism for regulating apoptosis.4,5
More than 15 viral homologs of anti-apoptotic Bcl-2 proteins have been identified in large 
double-stranded DNA viruses including adenoviruses, herpesviruses, and poxviruses.6,7 
Kaposi’s sarcoma-associated herpesvirus (KSHV or human herpesvirus 8) and Epstein-Barr 
herpesvirus (EBV or human herpesvirus 4) both express viral Bcl-2 homologs. Current 
understanding of the function of viral Bcl-2 proteins in infection and virulence is still 
evolving, and the roles of these proteins likely vary from virus to virus. Both EBV and 
KSHV latently infect humans, and most carriers present no symptoms. However, both 
viruses can give rise to malignancies in immunocompromised hosts, such as patients on 
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immunosuppression therapy following organ transplant or AIDS patients. A mutant EBV 
found in about 15% of Burkitt lymphomas engenders greatly enhanced apoptosis resistance 
to infected B cells, which was attributed to increased latent cycle expression of the EBV 
Bcl-2 protein BHRF1.8 This led to the discovery that BHRF1 is expressed at low levels in 
wild-type EBV-infected, latent Burkitt lymphoma cells and is important in preventing 
apoptosis triggered by aberrant cell proliferation signals from constitutive c-myc 
expression.8,9 The function of KSBcl-2, the KSHV viral Bcl-2, in oncogenesis or infection 
is less clear, but this protein may also act to counteract apoptosis driven by cell proliferation 
signals, in this case by a viral cyclin.10,11 KSBcl-2 has been shown to be important for the 
initial stages of lytic reactivation from latent infection.12 The murine gamma herpesvirus 
γHV68 expresses Bcl-2 homolog M11. Although γHV68 is not associated with cancer in 
mice, it has been proposed as a useful model system for studying KSHV and EBV, which do 
not infect mice, and for which cell lines have limited utility as models of viral infection.13 
M11 has been shown to be important for persistent replication and virulence during chronic 
infection.14
Despite playing a similar anti-apoptotic role, the three herpesvirus Bcl-2 proteins are not 
equivalent. KSHV and γHV68 are gamma-2-herpesviruses, and the synteny of the Bcl-2 
genes in these two viruses is similar, suggesting that their viral Bcl-2 proteins KSBcl-2 and 
M11 may share evolutionary origins.15 However, EBV is a gamma-1-herpesvirus, and its 
Bcl-2 homolog, BHRF1, is located in a different region in the genome. This suggests that 
ancestral BHRF1 may have been acquired in a separate horizontal gene transfer event, 
possibly originating from a different mammalian Bcl-2 homolog than KSBcl-2 and M11.3,15 
A key functional difference between the viral Bcl-2 homologs is that although KSBcl-2 and 
M11 are anti-autophagic, this is not true of BHRF1; EBV upregulates autophagy for non-
cell death purposes.6,7,16
Viral Bcl-2 proteins could conceivably function by mimicking a specific mammalian 
homolog. Alternatively, they could share roles played by several mammalian homologs, or 
even have distinct functions. The in vivo function of viral Bcl-2 homologs, and how it 
compares to that of their human counterparts, has not been extensively characterized. But 
some clues can be gleaned by looking at viral effects on the cell. Herpesvirus gene products 
can negatively regulate human Bcl-2 and Bcl-xL, suggesting that the viral Bcl-2 homologs 
may need to compensate for the decreased activity of these human homologs. For example, 
EBV transcription factor BZLF1 downregulates the cellular protein CD74, resulting in T-
cell evasion and decreased expression of Bcl-2 and Bcl-xL in B lymphoblastoid cell 
lines.8,17,18 An EBV-infected cell line was nevertheless recently shown to be dependent 
upon Bcl-xL for resistance to apoptosis, but as BHRF1 expression was not detected in this 
cell line, its role relative to human Bcl-2 homologs remains unclear.8,9,19 In the KSHV-
infected cell line Bcbl-1, KSBcl-2 is expressed at low levels and Mcl-1 at high levels. 
Bcbl-1 cells exhibited a response to a panel of BH3 peptides indicative of a dependence 
upon both Mcl-1 and KSBcl-2 for protection from apoptosis.10,11,19 KSHV also 
downregulates Bcl-2 activity by expression of a viral cyclin that directs cellular CDK6 to 
phosphorylate and inactivate Bcl-2. This may be advantageous for the virus because human 
Bcl-2 can impair cell cycle progression and be converted into a pro-apoptotic form by 
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caspase cleavage.11,12,20 KSBcl-2 and M11 can also fulfill the anti-autophagic roles of Bcl-2 
and Bcl-xL by binding Beclin-1.13,21,22 These findings illustrate that in addition to filling the 
anti-apoptotic niche, it may be advantageous for herpesviruses to use their Bcl-2 homologs 
to fulfill additional human Bcl-2 roles (e.g., in autophagy), but not others (e.g. pro-apoptotic 
and cell cycle regulatory roles). The functional analogies between human and viral Bcl-2 
homologs, and how any similarities or differences relate to BH3 binding profiles, remain to 
be elucidated.
The mechanistic details of protection from apoptosis rely on which pro-apoptotic Bcl-2 
family members each anti-apoptotic Bcl-2 homolog binds. The BH3 interaction preferences 
of the human anti-apoptotic Bcl-2 proteins have been extensively studied, with particular 
attention focused on the large differences between Bcl-xL and Mcl-1.14,23-28 BH3 motif 
binding is often tested using peptides ~20 residues in length, here referred to as BH3 
peptides. Bim, Bid, and Puma BH3 peptides all bind to the five main anti-apoptotic Bcl-2 
proteins, but sensitizer BH3 peptides such as Bad and Noxa are selective for different sets of 
anti-apoptotic receptors. Notably, Bad binds tightly to Bcl-xL, Bcl-2, and Bcl-w, but not 
Mcl-1, whereas Noxa preferentially binds Mcl-1.15,29,30 This distinction has long been used 
to group Bcl-xL, Bcl-2, and Bcl-w into a common specificity class and Mcl-1 into its own 
class. Bfl-1 is sometimes grouped into a class with Mcl-1, based on not binding to Bad and 
binding weakly to Noxa, Bik, and Hrk. However, human Bfl-1 does not bind two murine 
Noxa variants, distinguishing it from Mcl-1, which does bind these proteins.29-31 Viral 
protein BHRF1 has been shown to have a limited BH3 binding profile, binding only Bim, 
Bid, and Puma out of a set of 10 mammalian BH3 peptides tested.32 KSBcl-2 and M11 have 
more permissive binding and exhibit BH3 binding profiles more similar to that of Mcl-1 in 
that they show moderate binding to Noxa, but only very weak binding to Bad.22,32-34 
Further comparison of the binding specificities of viral and human Bcl-2 proteins may shed 
light on how viral Bcl-2 functions compare to human Bcl-2 functions, as BH3 binding 
specificity is a crucial determinant of anti-apoptotic Bcl-2 activity.
Studying the binding preferences of viral and human Bcl-2 homologs can also illuminate 
differences that could be exploited to design specific protein interaction inhibitors. Specific 
inhibitors of the viral Bcl-2 homologs would be useful for basic research and potentially for 
therapy. Early peptidic and small molecule inhibitors targeted at human Bcl-xL achieved 
inter-class specificity in that they showed no binding to Mcl-1, but did not distinguish 
between members of the Bcl-xL, Bcl-2, and Bcl-w class.23,35 Targeting Bcl-2 and Bcl-xL in 
cancers with Navitoclax, the clinical form of the small-molecule inhibitor ABT-737, led to 
thrombocytopenia due to the fact that platelets are dependent upon Bcl-xL for protection 
from apoptosis.36,37 A Bcl-2-specific small molecule, ABT-199, is achieving better success 
in clinical trials due to reduced off-target effects.38 This highlights the importance of 
specific targeting of Bcl-2 homologs for cancer therapy. Significant progress has been made 
identifying peptide inhibitors of individual human Bcl-2 family members including Mcl-1, 
Bcl-xL and Bfl-1.25,39,40 For viral Bcl-2 homologs, a computationally designed protein, 
BINDI, binds BHRF1 with picomolar affinity and >180-fold specificity over the human 
Bcl-2 homologs.41 BINDI is a 14 kDa protein that incorporates a BH3 helix but gains much 
of its specificity from contacts outside of the BH3 binding groove. When attached to an 
antibody-targeted intracellular delivery carrier, BINDI reduced tumor growth in xenograft 
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mouse models of EBV-positive human lymphoma, supporting BHRF1 as a candidate 
therapeutic target. A peptide variant of the BH3 motif of Beclin-1 was recently engineered 
that binds selectively to M11 over Bcl-xL, but the peptide had weak affinity for M11 (KD = 
6.4 μM).42.
In this paper we report comparisons of viral and human Bcl-2 homologs at the levels of 
sequence, structure, and binding similarity in order to identify which homologs are most 
similar. Drawing on experimental data and structural models, we then interrogated the 
boundaries of this similarity by designing BH3 peptide libraries and screening them for 
selective binders of KSBcl-2 and BHRF1. Analysis of the peptides identified in the screen 
shed light on sequence and structural determinants of the BH3 binding preferences of viral 
and human homologs. Further mutation of library peptides provided molecules with >1000-
fold specificity for binding KSBcl-2 and >70-fold specificity for binding BHRF1 over all of 
the human Bcl-2 homologs. These peptides could serve as reagents to probe and inhibit the 
function of viral Bcl-2 homologs in viral pathogenesis.
Results
Comparison of eight Bcl-2 homologs based on sequence identity, structure, and binding 
preferences
Protein sequence identity is often used to infer functional similarity. We compared the 
sequences of 8 anti-apoptotic Bcl-2 family homologs across the entire Bcl-2 domain 
(without the C-terminal trans-membrane helix or the N-terminal PEST domain of Mcl-1) 
(Fig. 1). The viral Bcl-2 homologs KSBcl-2, BHRF1, and M11 have very low sequence 
identity to the human homologs and to each other (10-21%, Fig. 1a). To assess the similarity 
of receptors in the regions that most directly influence BH3 helix binding, we computed the 
sequence identity over residues that line the BH3 binding groove (Fig. 1b). Residues that 
were included are within 7 Å of a peptide residue in at least one BH3-bound structure, as 
described in the Materials and Methods. Sequence identity in the binding groove is higher 
than in the overall Bcl-2 domain, and Bcl-2, Bcl-xL and Bcl-w form a subgroup sharing high 
sequence identity in this region (≥ 60%). Human homologs Bfl-1 and Mcl-1 share at most 
30% and 39% binding-groove identity with the Bcl-xL/2/w set, respectively, and share 38% 
identity with each other. The human Bcl-2 homologs with highest sequence identity to the 
viral Bcl-2 proteins, in the binding groove, are Bfl-1 and Mcl-1 for KSBcl-2 (28%, and 24% 
identity, respectively), Bcl-xL/2/w for BHRF1 (25-26% identity), and Bcl-xL and Bcl-2 for 
M11 (24% identity). Thus, the similarities between Mcl-1, Bfl-1, and the viral homologs are 
much less significant than those between Bcl-xL, Bcl-2, and Bcl-w, although Mcl-1, Bfl-1 
and KSBcl-2 do cluster together at a lower similarity threshold.
Abundant structural data exist for complexes of anti-apoptotic Bcl-2 proteins bound to short 
BH3 motif peptides; of the proteins discussed here, only KSBcl-2 lacks a structure bound to 
a BH3 peptide. The overall helical architecture is conserved between all of the anti-apoptotic 
Bcl-2 homologs, as illustrated in the structure alignment shown in Supplementary Fig. 1. 
The Cα RMSD varies from ~0.8-3.2 Å between structures of different Bcl-2 homologs. To 
examine the chemical similarity of the different binding grooves, we performed analyses 
using SiteMAP on receptor-peptide complex structures or homology models for all eight 
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Bcl-2 homologs. SiteMAP, originally designed for identifying small molecule binding sites, 
creates maps of hydrophobic, hydrogen-bond donor, and hydrogen-bond acceptor binding 
potential proximal to the protein surface.43,44 Our process for defining a similarity score 
based on the intersection of SiteMAP maps from different receptors is summarized in 
Supplementary Fig. 1 and explained in greater detail in the Materials and Methods. A 
summary of the similarities between all pairs of maps, computed as the sum of the 
intersections of physicochemical property maps for pairs of proteins, is shown in Fig. 2, 
where protein structures are clustered according to their intersection score profiles. Where 
available, we ran the SiteMAP analysis on multiple structures for each Bcl-2 homolog, 
including structures of the receptor with different BH3 peptides bound. Notably, different 
structures of the same receptor bound to different peptides clustered together, showing that 
this analysis is robust to small changes in conformation. To further test dependence on small 
changes in Bcl-2 conformation, we performed a restrained minimization without the peptide 
present for one structure of each homolog before running SiteMAP. The minimized structure 
grouped with the other structures of that homolog, though in some cases more distantly.
Consistent with the sequence-based analysis, SiteMAP results show that Bcl-xL, Bcl-2, and 
Bcl-w form a tight cluster. M11 also joins this group, despite having much lower sequence 
identity with these proteins than they share with each other. Viral proteins KSBcl-2 and 
BHRF1 clearly cluster with Mcl-1. But surprisingly, given its higher binding-groove 
sequence identity to Mcl-1 than to Bcl-xL/2/w, Bfl-1 clusters more closely to the Bcl-
xL/2/w/M11 group. Averaged similarity scores (shown in bold for boxed sets of structures in 
Fig. 2) show that Mcl-1 and KSBcl-2 are most alike in binding-groove chemical structure, 
despite the fact that Mcl-1 is more similar to Bcl-xL and Bfl-1 than to KSBcl-2 by sequence 
identity. The KSBcl-2 and Bcl-w maps are based on homology models, which are heavily 
influenced by the homologs with which they share the greatest sequence similarity, which 
are Bfl-1 and Mcl-1 for KSBcl-2 and Bcl-xL for Bcl-w. Therefore, the high similarity 
between these structures may be somewhat artificial, but it is consistent with other trends 
reported in this paper. While this manuscript was in preparation, a structure of a mutant Bcl-
w bound to a peptide corresponding to its own (mutated) BH3 domain was published.45 The 
Cα RMSD over helices 2-8 between our Bcl-w:Bak BH3 homology model and this Bcl-
w:Bcl-w BH3 structure is 1.2 Å, validating our Bcl-w model.
Binding of the viral and human Bcl-2 homologs to a small set of functionally validated 
human BH3 peptides has been previously reported and is summarized in Fig. 3a.22,30,32 
Recently, DeBartolo et al. reported dissociation constants for the five human Bcl-2 
homologs binding to 36 new, computationally identified candidate BH3 peptides from the 
human proteome.46 In Fig. 3b, we compare the binding patterns of the three viral Bcl-2 
homologs to those of the human homologs for these 36 BH3-like peptides. The dissociation 
constants were determined by fluorescence anisotropy binding experiments. Hierarchical 
clustering of KD values by Bcl-2 receptor shows similar trends for binding of the previously 
reported and functionally validated vs. new BH3 peptides. Bcl-xL, Bcl-2, and Bcl-w, which 
have high sequence identity and structural similarity with each other, cluster together as 
expected. BHRF1 and Bfl-1 are grouped together based on binding tightly to only a small 
number of peptides. KSBcl-2 and Mcl-1 cluster together in Fig. 3b and are in the same 
group in Fig. 3a, although there are a few notable differences in the binding profiles of these 
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two proteins. In Fig. 3b, peptides in the clusters marked with asterisks exhibit moderate-to-
tight binding to KSBcl-2 and also to Bcl-xL/2/w, but weaker binding to Mcl-1. We return to 
this point below.
Natural BH3 sequences have high variability, which makes it difficult to parse the 
determinants that underlie the observed binding patterns. To compare binding preferences in 
a more interpretable sequence space, we performed Bim BH3 substitution SPOT array 
analysis for KSBcl-2 and BHRF1. The SPOT array assay is used to test binding to hundreds 
of membrane-immobilized peptides in parallel, and has proven useful in published analyses 
of Bcl-2 family binding.47-49 Our viral Bcl-2 SPOT arrays included peptides with 18 
individual point mutations (excluding cysteine and methionine) at a set of 10 positions in 
Bim BH3 that were previously analyzed for human Bcl-2 protein binding (Fig. 4). We refer 
to BH3 peptide positions using a repeating-heptad nomenclature, with positions labeled a-g, 
which is shown for the full Bim BH3 sequence in Fig. 5c. The viral Bcl-2 arrays additionally 
included peptides with mutations in 3 positions in the N-terminal region of Bim, and 2 
positions in the C-terminal region. However, varying these terminal positions gave only 
small changes in binding signal in this assay, not readily distinguished from noise; we do not 
interpret observed differences at these positions here.
The peptide binding similarity of different Bcl-2 proteins can be assessed using the 
correlation of SPOT signals between receptors for a common set of 180 Bim BH3 variants 
tested for five human and two viral proteins. Previous analyses showed that of the five 
human proteins tested by SPOT analysis, only the Bcl-xL/w/2 arrays showed a high 
correlation of binding patterns.48 The correlation of the KSBcl-2 SPOT array signals with 
SPOT data for most human homologs was moderate (Pearson R = 0.71-0.80), with Bcl-xL 
having slightly lower similarity (R = 0.66). The BHRF1 SPOT array data were moderately 
correlated with data for KSBcl-2 and Mcl-1 (R = 0.75 and 0.71, respectively), but 
correlations with the other homologs were lower. Notably, despite exhibiting a similarly 
restrictive binding profile for natural BH3 peptides, Bfl-1 and BHRF1 show relatively low 
correlation between their SPOT array signals (R = 0.66), suggesting they arrive at their 
restrictive binding profiles through different mechanisms. Differences in positional 
preferences that can be dissected with the use of the SPOT data are discussed below.
Peptide libraries targeting KSBcl-2 and BHRF1 specificity
Peptide design using library screening has repeatedly led to molecules that discriminate 
between binding to Bcl-xL/2/w vs. Mcl-1 or Bfl-1 by large margins.23,26,28 It has been more 
difficult to design specificity between members of more closely homologous groups (e.g., 
Bcl-xL vs. Bcl-2/w or Bfl-1 vs. Mcl-1).39,40 Above, we showed that KSBcl-2 and BHRF1 
have BH3 binding patterns most similar to those of Mcl-1 and Bfl-1, respectively. We 
interrogated the boundaries of this similarity by designing and screening Bim BH3-based 
libraries for peptides that could bind KSBcl-2 or BHRF1 selectively (Fig. 5). To increase 
our chances of success, we used experimental binding data and structure-based models of 
BH3 peptide binding preferences to design libraries enriched in mutations predicted to 
provide specificity for KSBcl-2 or BHRF1. The libraries were based on mutating the Bim 
BH3 motif, for which we have rich binding data from prior work. Specifically, we designed 
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the libraries using mutational data from SPOT arrays and predictions made using 
STATIUM, a statistical potential that can evaluate mutations based on analysis of human or 
viral Bcl-2 crystal structures or homology models.46,48 We also used Illumina sequencing 
data from a yeast surface display library of Bim BH3 variants previously screened for 
KSBcl-2 binding.25 The computationally assisted library design process (described in 
further detail in the Materials and Methods) focused on including residues that were 
tolerated by the viral Bcl-2 proteins and that weakened binding to Mcl-1 and, for the BHRF1 
library, Bfl-1. Despite moderate sequence identity between KSBcl-2 and Bfl-1, we did not 
consider Bfl-1 to be a competitor difficult to discriminate against, because we have 
previously discovered mutations that favor KSBcl-2 over Bfl-1 binding, and we included 
these in the library.25 We also prioritized inclusion of a few mutations known to disfavor 
Bcl-xL, Bcl-2, and Bcl-w binding (e.g. non-aromatic residues at position 4a). 23,24
Nine positions in Bim were mutated, and the theoretical libraries designed using our 
optimization protocol are shown in Fig. 5c. The heptad register of Bim is given below each 
position. We chose to vary the four conserved hydrophobic positions 2d, 3a, 3d, and 4a, 
because the Bcl-2 homologs show strong, differential preferences for mutations at these 
positions.23,50 We also included variation at position 2a, because the structural environments 
around this position in the viral receptors exhibit differences from the environment in Mcl-1. 
Specifically, Mcl-1 has an arginine that forms a salt bridge with glutamate at 2a in Bim that 
is lacking in the viral receptors.24 The four remaining positions chosen for design, 2e, 2g, 
3b, and 3g, are generally occupied by small or polar/charged residues in native BH3 
sequences, as they are on the sides of the BH3 helix and are more solvent exposed. The 
library designs are presented, along with an indication of which residues were included for 
affinity or specificity, in Supplementary Tables 2 and 3.
The eCPX E. coli surface display system has been used previously to display and sort BH3 
peptide libraries.26,51 We optimized it for affinity-based sorting by adding a FLAG-tag N-
terminal to the BH3 peptide that can be used to detect the expression level of each library 
member (Fig. 5a). A representative fluorescence activated cell sorting (FACS) plot 
illustrating the correlation between peptide cell-surface expression and binding to KSBcl-2 
for a single clone is shown in Fig. 5b. We sorted the designed libraries by FACS in a series 
of positive, negative, and competition sorts to identify high affinity and selective binders of 
the viral Bcl-2 proteins, as illustrated in Supplementary Fig. 2 and detailed in the Materials 
and Methods. Human homologs Mcl-1, Bfl-1, and Bcl-w were used as competitors in the 
KSBcl-2 library sorting, and Mcl-1 and Bfl-1 were used for the BHRF1 library. Pools of 
clones isolated from rounds of sorting are designated KL1-KL8 for KSBcl-2 and BL1-BL8 
or BL5’-BL8’ for BHRF1 (see Methods and Supplementary Figure 2). FACS analysis was 
performed on the naïve and final pools for both libraries (Supplementary Fig. 3). This 
analysis showed that although the naïve libraries contained more Mcl-1 binders than viral 
Bcl-2 binders, the final sorted library pools consisted of tight viral Bcl-2 binders with 
modest margins of specificity against Mcl-1, and larger margins of specificity against Bfl-1, 
Bcl-w, and Bcl-2.
To follow the progress of sorting and to isolate clones for further analysis, we sequenced 
clones from later library pools. From the KL6 and KL8 library pools, we sequenced 24 and 
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20 clones, respectively, and found a total of 16 unique sequences. Among four BHRF1 
library pools from two different sorting schemes (see Materials and Methods), we obtained 
32 unique sequences. Peptide sequences and the frequencies with which they were found in 
the library pools are given in Supplementary Table 4. To provide more sequences for 
analysis of library design success and mutation enrichment trends, the naïve libraries (KL0 
and BL0) and pools 1, 3, 5, 6, 7, and 8 were sequenced using Illumina technology for each 
library. The sequence filtering process and number of reads for each pool are described in 
the Materials and Methods and in Supplementary Table 5. Sequence data show that the 
library screens resulted in distinct residue preferences at select positions, as shown by logos 
constructed from unique, filtered sequences in the eighth (final) pools (Fig. 5c). Many of the 
trends observed support the predictions of the SPOT arrays (PSSMSPOT models) and the 
STATIUM models. For example, at position 2a, the wild-type glutamate residue was 
selectively lost from the KSBcl-2 library, while the other five possible mutations were 
maintained. And in the BHRF1 library, isoleucine was enriched at 2a. Position 2a was not 
mutated on the SPOT arrays, but the STATIUM models predicted that most mutations from 
glutamate at 2a – including isoleucine – would provide specificity for binding either of the 
viral Bcl-2 receptors over Mcl-1, and our library results validate the STATIUM predictions. 
In the BHRF1 library screen, there was a strong preference for isoleucine over leucine at 2d 
and 3a. The SPOT arrays indicated that BHRF1 strongly prefers the wild-type isoleucine at 
2d, and can tolerate both isoleucine and leucine at 3a. The preference for isoleucine over 
leucine at 3a in the BHRF1 library results (Fig. 5c) may arise in part because this 
substitution provides specificity over some of the human receptors, as described in a later 
section. At peptide positions along the sides of the BH3 binding groove, such as 2e and 3b, 
the SPOT arrays also accurately reflected preferences. For example, the SPOT arrays 
indicated that KSBcl-2 is more tolerant of a variety of residues at 2e than are Bcl-xL, Bcl-2, 
and Bfl-1, whereas BHRF1 has greater tolerance at 3b than this same group of receptors, and 
this was reflected in the library results.
To evaluate the overall agreement between predictions made by the models used in our 
library design protocol and the library enrichment results, we compared the model scores for 
all point mutations with the enrichment of individual mutations during screening (Fig. 6). 
The SPOT arrays were converted to position-specific scoring matrices (PSSMs) by taking 
the logarithm of the mutant intensity divided by the average wild-type intensity (giving 
PSSMSPOT models).23,48 Enrichment was measured as log2(frequency of mutation in unique 
sequences in final pools KL8 or BL8’/frequency in the naïve pools KL0 or BL0). 
Enrichment is indicated by color in Fig. 6, with enriched mutations in shades of orange to 
red. Scores for the wild-type Bim residues are indicated by gray lines on the plots in Fig. 6, 
such that points that fall in the lower right quadrant of each plot correspond to point 
mutations predicted by the models to provide enhanced affinity for the target viral Bcl-2 and 
specificity against Mcl-1. Many of the most enriched mutations in each library fall into this 
quadrant for the PSSMSPOT models (Fig. 6a and 6c). For example, 83% of the enriched 
mutations for KSBcl-2 (log2(frequency in final pool/frequency in naïve pool) > 0) fall in this 
quadrant, as do 58% of the enriched mutations for BHRF1. The STATIUM model 
predictions did not agree as well with the screening results, but enriched residues had better 
viral protein binding scores than non-enriched residues: 86% of the mutations with 
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log2(frequency KL8/KL0) > 0 had STATIUMKSBcl-2 scores > −3, whereas only 59% of un-
enriched residues had scores this high. For BHRF1, 73% of mutations with log2(frequency 
BL8’/BL0) > 0 had STATIUMBHRF1 scores > −3, compared to 56% of un-enriched 
residues. The high correlation of STATIUM scores for KSBcl-2 or BHRF1 binding with 
scores for Mcl-1 binding reflects the predicted difficulty of distinguishing interactions 
between the viral proteins and Mcl-1. This is also seen, to a lesser degree, in the SPOT 
results and is consistent with our experimental observations.
Binding of library-derived peptides to 8 Bcl-2 homologs
We selected 22 peptides that sample a variety of sequence features to test in direct 
fluorescence anisotropy binding experiments. Peptide names designate the library (‘KL’ or 
‘BL’) followed by the sorting pool from which they were sequenced, followed by an 
arbitrary numerical designation. References to KL and BL peptides refer specifically to the 
peptides tested in solution binding experiments. The peptide names with alphabetical 
designations were chosen from the deep sequencing results, either because they represented 
a consensus sequence or because they contained enriched substitutions not sampled in the 
conventionally sequenced clones. The 22 peptides were tested for binding to all 5 human 
and 3 viral receptors.
A heat map of the KD values is shown in Fig. 7, clustered by receptor binding profile 
similarity (KD values with 95% confidence intervals are given in Supplementary Table 6). 
The binding patterns of peptides identified from the two libraries have a clear distinction. 
Most of the peptides identified by screening for binding to BHRF1 also bound to KSBcl-2, 
M11 and Mcl-1. In contrast, peptides identified on the basis of binding to KSBcl-2 only 
bound strongly to KSBcl-2 and Mcl-1. Despite our use of competitive screening against 
Mcl-1, it is notable that all of the peptides that bound to KSBcl-2 or BHRF1 also bound 
tightly to Mcl-1. Binding to Bcl-2, Bcl-xL, and Bcl-w was substantially weaker for all of the 
peptides, consistent with the distinct sequence and structural properties of these receptors. 
Binding to Bfl-1 was universally very weak for peptides from both libraries, although Bfl-1 
bound tightly to positive control peptides. This trend is especially interesting given the 
similarity between the native BH3 binding profiles of BHRF1 and Bfl-1.
Specificity mechanisms underlying receptor binding similarity patterns
We analyzed the binding patterns observed for different Bcl-2 proteins by integrating data 
from the SPOT arrays, the SiteMAP structural analysis and solution binding studies of 
peptides and selected point mutants. Our analyses suggested mechanisms by which the 
library peptides achieve specificity. These mechanisms will be discussed on three levels. 
First, we discuss peptide sequence features that distinguish binding to the three viral 
homologs KSBcl-2, BHRF1, and M11. Second, we address sequence and structural features 
that differentiate peptides that bind to the KSBcl-2/Mcl-1/BHRF1 vs. Bcl-xL/2/w/Bfl-1 
groups. Finally, we discuss mutations that contribute to the modest level of specificity 
achieved by some peptides for binding to the viral Bcl-2 proteins over Mcl-1.
To investigate the origins of binding differences between the viral Bcl-2 homologs, we 
tested residue substitutions in Bim BH3 that were common in the peptides identified from 
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the libraries. Threonine was enriched at position 2e in the KSBcl-2 library (Fig. 5c), and the 
specificity of Bim_A2eT for KSBcl-2 and Mcl-1 has been addressed in prior work.25 Our 
nomenclature for mutants lists the parent peptide (Bim) followed by the wild-type residue 
that was mutated (A), the heptad position (2e) and the new residue identity at that site (T). 
The alanine-to-threonine mutation in Bim_A2eT weakens binding to Bfl-1, Bcl-xL, Bcl-2 
and Bcl-w.25 Here, we show that this mutation also weakens BHRF1 and M11 binding 
(Table 1). Another peptide position that can favor KSBcl-2 binding is 2g. In contrast to the 
BHRF1-binding peptides in Fig. 6, which have glutamine, lysine or glutamate at position 2g, 
many of the KSBcl-2-binding peptides that we analyzed have a glycine at this site. BHRF1 
binding is weakened dramatically by the two mutations in Bim_A2eT_E2gG, and 60% of 
the KL peptides tested combine the E2gG mutation with a larger residue (proline, threonine, 
aspartate, or histidine) at 2e. This likely explains why BHRF1 shows limited binding to 
many of the KSBcl-2 library peptides. As for BHRF1 specificity determinants, serine at 
position 3b is common in the BHRF1 library peptides. Bim_R3bS binds tightly to BHRF1 
but the serine mutation weakens binding to Bfl-1, Bcl-w, Bcl-2, and M11 by ~4-9-fold when 
introduced into Bim BH3 (Table 1), providing a partial explanation of the BHRF1 library 
peptide specificity. Notably, many of the BHRF1 library peptides bind more tightly to M11 
than does wild-type Bim BH3, suggesting that even though R3bS weakens M11 binding, 
other mutations present in the BL peptides must compensate for this effect.
The four BH3 positions that are conserved as hydrophobic (2d, 3a, 3d and 4a) have been 
demonstrated to make strong contributions to human Bcl-2 specificity patterns.23,24,27,50 
Here, we observed that these positions are important for differentiating binding to KSBcl-2/
Mcl-1/BHRF1 vs. Bcl-xL/2/w/Bfl-1. The SPOT arrays indicated that viral proteins BHRF1 
and KSBcl-2, and human proteins Mcl-1 and Bcl-w, are broadly tolerant of substitutions at 
position 4a (Fig. 8a). We observed the same trend in library screening. Several of the tested 
KL peptides had an F4aL substitution, and an F4aE mutation was found in a minority of the 
BL peptides. Notably, Bcl-xL and Bcl-2 showed no binding to these peptides (Fig. 7), in 
keeping with the observation made in several past studies that Bcl-xL and Bcl-2 have a more 
enclosed 4a pocket that favors aromatics of complementary size and shape.23-25,52 Human 
Mcl-1 and viral KSBcl-2, M11, and BHRF1 appear to have similar preferences at 
hydrophobic position 3a. The BHRF1 library peptides showed a strong preference for 
isoleucine at position 3a, where most natural BH3 peptides have a leucine. The Bim 
substitution SPOT arrays indicate that BHRF1, KSBcl-2 and Mcl-1 exhibit no loss in 
affinity for the L3aI mutation, whereas Bfl-1, Bcl-xL, Bcl-2, and Bcl-w binding is weakened 
(Fig. 8a). The shape of the 3a pocket is influenced by two positions in helices 4 and 5 that 
are underlined in Fig. 1c. KSBcl-2, Mcl-1 and BHRF1 have either a β-branched isoleucine 
or valine, or a long but flexible methionine on helix 4, where the other receptors have 
glutamate or leucine, which leave less space for a branched Cβ at peptide position 3a. The 
extra space for a branched Cβ can be seen in KSBcl-2, BHRF1, and Mcl-1 hydrophobic 
SiteMAPs (Fig. 8b). M11 also has a leucine on helix 4, but has a unique glycine on helix 5, 
which may allow more space for a branched Cβ than is provided by the alanine or threonine 
found in the other receptors. Thus, preferences at two of the conserved hydrophobic 
positions, 4a and 3a, distinguish the binding properties of the library peptides, with KSBcl-2, 
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BHRF1, Mcl-1, and M11 exhibiting broader tolerance for residue substitution than Bfl-1, 
Bcl-xL, and Bcl-2.
Our libraries were designed and screened for peptides that would bind to the viral proteins in 
preference to all human proteins including Mcl-1. Specificity over Bcl-xL, Bcl-2, Bcl-w, and 
Bfl-1 was readily achieved, but the library peptides showed only modest specificity (2- to 
20-fold) over Mcl-1. We traced much of the viral protein vs. Mcl-1 binding specificity to 
hydrophobic interactions at positions 3d and electrostatic interactions at positions 2g and 3g. 
Most KSBcl-2 binders that we characterized had leucine at 3d, and most BHRF1 binders had 
valine. SPOT arrays indicate that Bcl-xL, Bcl-2, Bcl-w, Bfl-1, and KSBcl-2 are highly 
tolerant of mutations at 3d, whereas BHRF1 prefers valine and tolerates alanine (Fig. 8a). 
However, Mcl-1 is highly intolerant of any mutation of I3d according to both the SPOT 
array and a previous BH3 peptide library sorted for Mcl-1 specificity (Fig. 8a).23 Comparing 
the region surrounding position 3d using SiteMAP, we found that Mcl-1 structures form a 
cluster separate from the other homologs (Fig. 8c). The structural mechanism behind the 
position 3d tolerance exhibited by Bcl-xL may be related to the multiple different 
conformations accessible at the helix 2-3 bend (Supplementary Fig. 4). These conformations 
are stabilized by different arrangements of a cluster of three aromatic residues highlighted in 
red in Fig. 1c, and they result in different environments for the peptide side chain at position 
3d in different structures. These three aromatic residues form a motif that is also present in 
Bcl-2, Bcl-w, and M11. In contrast to Bcl-xL, all solved Mcl-1 structures have a similar 
conformation in the helix 2-3 bend. Until more structures are solved of KSBcl-2 and BHRF1 
bound to diverse peptides it will remain unclear how they accommodate residues other than 
isoleucine at 3d. However, the different degrees of tolerance at 3d between KSBcl-2 (very 
tolerant), BHRF1 (moderately tolerant), and Mcl-1 (very intolerant) may arise from the 
different residues at the structural motif between helices 2 and 3 (L/K/F for KSBcl-2, I/N/F 
for BHRF1 and V/H/F for Mcl-1, in the same positions as the aromatic residues in the 
aforementioned Bcl-xL motif; see Fig. 1).
Charge patterns at positions 2g and 3g also contribute to selectivity for viral proteins over 
Mcl-1. For example, KL8-7 and KL8-16 both bind with KD < 1 nM to KSBcl-2, but KL8-7 
has a KD of 21 nM for Mcl-1, whereas KL8-16 has a KD of 3.9 nM. The only difference 
between these peptides is an arginine at position 2g in KL8-7 versus a glutamine in KL8-16 
(Supplementary Table 6). Likewise, mutation of E3g (the wild-type residue in Bim) to 
arginine in BL peptides reduced affinity to Mcl-1 by approximately 3-fold. By comparing 
BL6-19 (E3g) to BL_d (R3g), or BL_c (E3g) to BL_b (R3g), it can be seen that only 
BHRF1, Bfl-1, and M11 tolerate R3g without a significant loss of affinity (Supplementary 
Table 6; the glutamate to arginine mutation is the only difference between these peptide 
pairs). Consistent with this, BHRF1 and Bfl-1 are the only receptors that show large patches 
of donor density proximal to position 3g in their SiteMAPs (Fig. 8d).
Designed peptides with improved specificity for KSBcl-2 and BHRF1 vs. Mcl-1
To increase the specificity of our designed peptides against Mcl-1, we considered positions 
beyond the 9 that were varied in our libraries. We searched for differences between the viral 
homologs and Mcl-1 in sequence and structure, and mined our binding data and the 
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literature for observations that could guide further optimization. Based on this analysis, we 
made additional mutations at C-terminal positions 3f and 4e that improved specificity, as 
described below.
Among the 36 BH3-like peptides in Fig. 3, 9 peptides showed ≥10-fold tighter binding to 
KSBcl-2 than to Mcl-1 (fold specificity and sequences are in Fig. 9a). Three out of the nine 
KSBcl-2-specific peptides had arginine or lysine at position 4e. Boersma et al. showed that 
Mcl-1 binding to Bim BH3 is weakened by a Y4eK mutation, which may arise in part from 
repulsion from an arginine present on helix 2 and/or from the loss of a favorable aromatic 
interaction with a phenylalanine on helix 8 (both highlighted in green in Fig. 1c, with the 
interactions in the Mcl-1:Bim BH3 structure shown in Fig. 9b).50 KSBcl-2 and BHRF1 have 
negatively charged residues along the peptide interface with helix 2 (green in Fig. 1c), and 
helix 8 in these proteins lacks the aromatic residue present in the human homologs. Finally, 
STATIUM predicts that substitution of tyrosine with lysine imparts a preference for 
KSBcl-2 over Mcl-1 binding, but is also moderately disruptive for KSBcl-2 binding. To test 
the role of lysine at position 4e, we made a Y4eK substitution in the background of the most 
specific KL and BL peptides (KL6-7 and BL6-22). KL6-7_Y4eK maintained tight binding 
to KSBcl-2 (KD of 2.9 nM) but Mcl-1 binding was weakened by 350-fold; this peptide was 
195-fold more specific for KSBcl-2 over Mcl-1 than KL6-7 (Table 2). The other Bcl-2 
homologs displayed no binding to KL6-7_Y4eK (Supplementary Table 6). Y4eK also 
improved the specificity of BL6-22 for BHRF1 by 3.6-fold, though it reduced BHRF1 
binding affinity from a KD of 2.2 nM to 30 nM. BL6-22_Y4eK had 70-fold specificity for 
BHRF1 over Mcl-1 and >100-fold specificity over the other human Bcl-2 homologs (no 
binding detected, Supplementary Table 6). Thus, Y4eK is the single strongest contributor to 
specificity between KSBcl-2/BHRF1 and Mcl-1 that has been identified.
Our library design strategy favored residues predicted to be non-disruptive for viral Bcl-2 
binding. While appropriate for obtaining high affinity binders, this strategy may exclude 
mutations that provide specificity at the cost of affinity. We identified an example of such a 
mutation at peptide position 3f. Huang et al. showed that mutation of aspartate at 3f to 
alanine in a Bak BH3 peptide weakened Bcl-xL binding more than KSBcl-2 binding.53 
SPOT arrays also showed that mutation of aspartate at 3f in Bim to any other residue 
abolished binding to Mcl-1, Bfl-1, Bcl-2, and Bcl-xL, but only weakened KSBcl-2 binding. 
To test the idea that substitutions at position 3f might provide specificity by decreasing 
Mcl-1 binding more than KSBcl-2 binding, we introduced D3fA into KL6-7. This mutation 
reduced binding to KSBcl-2 110-fold (KD 180 nM), but weakened binding to Mcl-1 to the 
extent that it was undetectable up to 5000 nM (Table 2). Structural analysis suggests a 
plausible mechanism for this differential effect. Mcl-1 forms a salt bridge between an 
aspartate at the end of helix 4 and the BH1 motif arginine at the N-terminus of helix 5. This 
interaction appears to position the arginine optimally for interaction with the BH3 aspartate 
at 3f (Fig. 9c). Although KSBcl-2 also has an aspartate in the helix 4-helix 5 loop, it has an 
insertion of 3 residues preceding the aspartate, relative to Mcl-1 (Fig. 1c). In homology 
models of KSBcl-2 complexes built on three different alignments with Mcl-1, the 
interactions observed in Mcl-1 were not able to form in an optimal configuration. Thus, the 
interaction between the 3f aspartate and the BH1 arginine may be weaker in KSBcl-2:BH3 
complexes than in Mcl-1 complexes. We tested two other mutations with the potential to 
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improve specificity for KSBcl-2 over Mcl-1 (G3eC and I2dR, see notes in Supplementary 
Table 6), but these had equally detrimental effects on KSBcl-2 and Mcl-1 binding.
We also synthesized and tested a composite of the most KSBcl-2 specific library peptides, 
KL6-7 and KL8-7. KScomp has the N-terminal 5 substitutions present in the KL8-7 peptide, 
including the 2gR specificity mutation, and the 2 C-terminal substitutions of KL6-7 (3gG 
and 4aL). A 3dT substitution was also introduced, as the SPOT arrays suggested that 
threonine would provide more specificity against Mcl-1 than leucine. According to deep 
sequencing data, KScomp was preserved in our library from the naïve pool to pool KL5, but 
at a very low frequency (<0.0007%). We found that KScomp had reduced affinity for 
KSBcl-2 (13 nM KD) when compared to library peptides that were tested from pools KL6 
and KL8 (all had KD values of ~ 1 nM), but KScomp had 39-fold specificity over Mcl-1, 
which is greater than the specificity of the other tested KL peptides. Given its low 
frequency, KScomp may have been lost from the library by chance. However, its 10-fold 
lower affinity than the peptides that survived the screen suggests that our sorting conditions 
were too stringent for KSBcl-2 affinity to enrich this peptide.
Discussion
As evolutionarily distant homologs of the mammalian anti-apoptotic Bcl-2 proteins, viral 
Bcl-2 proteins offer an interesting opportunity to study structure-function relationships in 
binding. In this paper, we characterized KSBcl-2, BHRF1 and M11 in terms of their 
sequence, structural, and binding-profile similarity to the human Bcl-2 homologs. The 
binding specificities of the different proteins provided insights into possible functional 
analogy, whereas analysis of sequence and structural similarity was useful for testing 
whether or not these measures are a good proxy for biochemical function similarity. We 
found that the low sequence identity of the human and viral proteins primarily emphasizes 
the high degree of divergence and is not particularly useful in identifying similarities 
between these groups. The SiteMAP results capture the clear similarities between Bcl-xL, 
Bcl-2, and Bcl-w that are apparent from sequence analysis, but present a more nuanced view 
of the more dissimilar homologs Mcl-1, Bfl-1, KSBcl-2, and BHRF1. Though by sequence 
identity Bfl-1 is closest to Mcl-1, the SiteMAP results suggests that Bfl-1 has structural 
features closer to those of the xL/2/w/M11 group. Conversely, BHRF1 has higher sequence 
identity to Bcl-xL and Bcl-2, but appears structurally more similar to Mcl-1. KSBcl-2 is 
similar to Mcl-1 by structure, but to a lesser degree than the highly similar xL/2/w/M11 
group. The structural relatedness of both KSBcl-2 and BHRF1 to Mcl-1 was reflected in the 
library screening experiments, in which it was difficult to achieve large margins of binding 
specificity over Mcl-1.
By looking at parallels in binding similarity and structure we can make hypotheses about 
functional similarity between the viral and human Bcl-2 homologs. For example, BHRF1 
shows structural similarity to Mcl-1, and appears to have BH3 binding preferences 
representative of a narrower subset of the binding preferences of Mcl-1. The restrictive 
binding of BHRF1 to only Bim, Bid, and Puma and the pro-apoptotic effectors Bak and Bax 
is reminiscent of human Bcl-b and viral Bcl-2 homolog F1L from vaccinia virus. Bcl-b only 
binds Bim, Bik and Bax, and F1L is reported only to bind Bim, Bak, and Bax, out of a set of 
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pro-apoptotic BH3-only proteins and Bax and Bak.54,55 BHRF1 binds Bak in cells, and its 
interaction with Bim appears to be especially critical to its anti-apoptotic activity in 
lymphocytes.56 The restrictive binding profiles of BHRF1 and F1L may be a strategy 
employed by viruses either to focus on only the most critical activators and effectors of 
apoptosis, or to prevent off-target effects by avoiding the “moonlighting” functions of 
human Bcl-2 homologs in autophagy, mitochondrial homeostasis, or other pathways.57
M11 and KSBcl-2 have binding preferences similar in many respects to those of Mcl-1 (Fig. 
3). However, structural similarity suggests that M11 also has features similar to the Bcl-
xL/2/w class, whereas KSBcl-2 is closest to Mcl-1 by both structure and binding. As 
previously noted, both KSBcl-2 and M11 bind Beclin-1 and prevent autophagy as an 
important part of their cellular function.21,22 Bcl-2 and Bcl-xL also bind Beclin-1 to prevent 
autophagy; Mcl-1 binds Beclin-1 more weakly.58 However, KSBcl-2 and M11 do not bind 
tightly to the classical Bcl-2/xL/w binder, Bad, but do bind the Mcl-1 binder, Noxa.32,34,53 It 
will be interesting to investigate functionally why KSBcl-2 and M11 have binding 
characteristics of both the Bcl-2/xL/w and Mcl-1 classes. Much of the viral Bcl-2 literature 
only focuses on comparisons between viral Bcl-2 and human Bcl-2 or Bcl-xL function. Our 
results suggest that an investigation of the relationship between viral Bcl-2 and Mcl-1 
function would be informative in discerning the relationship between the roles played by 
these viral and human Bcl-2 homologs.
Several lessons can be learned from our attempts to design KSBcl-2 and BHRF1 specific 
BH3 peptides. First, trade-offs between affinity and specificity must be considered when 
dealing with homologs with very similar binding preferences, such as the viral Bcl-2s and 
Mcl-1. The importance of such trade-offs has been previously discussed in the context of 
protein-protein interaction design.59,60 Our library screen imposed criteria on both affinity 
and specificity, but with an emphasis on tight binding. As a consequence, we did not 
identify viral Bcl-2 selective peptides that had weakened binding to KSBcl-2 and BHRF1, 
such as KScomp (Table 2). Only very tight binders (Kd ~1 nM) survived to round 8. 
Screening conditions could be adjusted to maintain destabilizing but specific mutations by 
relaxing target affinity requirements in the design stage and reducing the stringency of 
screening. Peptides identified in this way could then be further optimized for tight binding. 
Another consideration in achieving specific binders is library diversity. Discriminating 
homologs with very similar binding preferences such as KSBcl-2 and Mcl-1 may require 
broader exploration of sequence space than can be achieved from screening just one library 
of ~107 molecules, or may require more precise selection of the sequences to be screened. 
For example, we did not vary position 4e in our library, the site of our most specific 
mutation, because we were limited by library size. Yet modeling using STATIUM, as well 
as hints from the literature, indicated this as a promising substitution. A recent paper by 
Dutta et al. also found that the Y4eK mutation imparted specificity for Bcl-xL over Bcl-2, 
suggesting that positions outside the core BH3 motif can strongly influence specificity.39 
Searching sequence space more extensively, with larger libraries or multiple rounds of 
library design and sorting, could accelerate discovery.
In this work we ultimately identified selective peptide inhibitors of viral Bcl-2 family 
proteins KSBcl-2, BHRF1 and M11 by various means, including library screening, rational 
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mutagenesis and profiling of BH3-like sequences previously identified in the human 
proteome. Although we did not sort a library for M11 specificity, one of the 36 BH3-like 
peptides identified from the proteome, AGBL2 showed moderate binding to M11 (210 nM), 
and at least 20-fold weaker binding to all of the other Bcl-2 homologs (Supplementary Table 
1). For use as a research reagent to specifically inhibit M11, this offers a 30-fold 
improvement in affinity over the existing M11-specific Beclin-1 mutant.42 Several of our 
BL peptides also have higher affinity for M11 (~1 nM) than is offered by natural BH3 
sequences, although these peptides show only moderate specificity over Mcl-1. The Y4eK 
mutants of the most specific KL and BL peptides (KL6-7_Y4eK and BL6-22_Y4eK) 
achieved large margins of specificity over all of the human Bcl-2 homologs. KL6-7_Y4eK 
is an especially promising peptide for future studies of KSBcl-2, as it binds very tightly and 
selectively to this protein.
As recently demonstrated by the use of a designed protein inhibitor of BHRF1 to suppress 
tumor growth in a mouse xenograft model of Epstein-Barr-positive human lymphoma, anti-
viral Bcl-2 agents have potential for use in disease therapy.41 Large proteins face obstacles 
in terms of intracellular delivery, and in this respect the much smaller designed peptides 
presented here may have advantages. More immediately, designed potent and selective 
inhibitors of viral Bcl-2 proteins can provide useful reagents for studying the function of 
viral Bcl-2 homologs in herpesvirus-associated pathologies, and for testing the extent to 
which these proteins contribute to cancer onset or progression.
Materials and Methods
Sequence identity, homology modeling and SiteMAP
Multiple-sequence alignments of Bcl-2 family proteins were manually constructed based on 
preliminary Clustal alignments and structural analysis. For calculation of sequence identity 
in the BH3 binding groove, Pymol was used to select residues of the Bcl-2 homologs within 
7 Å of the BH3 peptide. Structures used for this were: 2PQK(Mcl-1:Bim)24, 2WH6 
(BHRF1:Bim)64, 2VM6 (Bfl-1:Bim)63, 3FDL (Bcl-xL:Bim)62, 2XA0 (Bcl-2:Bax)65, 3BL2 
(M11:Beclin-1)22, and the homology models of KSBcl-2 and Bcl-w bound to Bim. An 
inclusive set of groove residues was defined to include any residue found within 7 Å of any 
peptide atom in any structure. See Fig. 1c for alignments.
Homology models of KSBcl-2 and Bcl-w were built using MODELLER (version 9.1).71,72 
The KSBcl-2:Bim complex was modeled on 2PQK24, 2WH664, 1O0L73, 2VM663, 3FDL62, 
and 1G5M74. The Bcl-w:Bim complex was modeled on 3FDL, 1G5M, 2PQK, and 2VM6. 
The KSBcl-2:Bak complex was modeled on 3PK175 and 2XPX64. The Bcl-w:Bak complex 
was modeled on 1BXL76 and 2XA065.
For SiteMAP (SiteMap, version 3.0, Schrödinger, LLC, New York, NY, 2014) structure 
analysis, the following PDB IDs were aligned to 2PQK (Mcl-1:Bim)24: 2VM6 
(Bfl-1:Bim)63, 3I1H (Bfl-1:Bak) and 3MQP (Bfl-1:Noxa) (NESG, unpublished), 2VOG 
(murine Bfl-1: Bmf)77, 2VOF (murine Bfl-1:Puma)77, 2VOH (murine Bfl-1:Bak)77, 2VOI 
(murine Bfl-1:Bid)77, 2WH6 (BHRF1:Bim)64, 2XPX (BHRF1:Bak)64, 3FDL (Bcl-
xL:Bim)62, 1BXL (Bcl-xL:Bak)76, 1G5J (Bcl-xL:Bad)78, 3IO8 (Bcl-xL:Bim L12F)62, 2PON 
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(Bcl-xL:Beclin-1)79, 3PK1 (Mcl-1:Bax)75, 2KBW (Mcl-1:Bid)80, 3KJ0 (Mcl-1:Bim 
I2dY)24, 3KJ1 (Mcl-1:BimI2dA)24, 3KJ2 (Mcl-1:Bim F4aE) 24, 3BL2 (M11:Beclin-1)22, 
2XA0 (Bcl-2:Bax)65, and homology models of Bcl-w and KSBcl-2 bound to Bak and Bim 
BH3s. The following structures were relaxed using minimization in Maestro in the absence 
of the peptide (minimization uses the OPLS_2005 force field and proceeds until no 
movements are >0.05 Å) and were aligned to 2PQK using just the equivalent receptor 
positions: 2PQK, 2WH6, 2VM6, 3FDL, 3BL2, 2XA0, and the KSBcl-2 and Bcl-w:Bim 
models. Cealign in PyMOL (version 1.3, Schrödinger, LLC) was used to do the alignments 
based on the Cα atoms of helix 2, the helix4/5 region, and peptide regions of the structures. 
The following residues were used for the alignments: 208-220, 243-280, and 6-17 for 2PQK; 
32-44, 68-105, and 148-159 for 2VM6; 45-57, 80-117, and 58-69 for 2WH6; 32-103, 
127-163, and 59-70 for 2XA0; 36-48, 68-104, and 110-121 for 3BL2; 85-97, 120-156, and 
90-101 for 3FDL; 31-43, 63-103, and 153-164 for KSBcl-2; 41-53, 76-112, and 164-175 for 
Bcl-w. The numbering for KSBcl-2 and Bcl-w refers to the residue number in the natural 
gene, with the third set of numbers referring to BH3 positions 2d-4a. Equivalent residue 
numbers to those listed above were used to align all structures of each homolog. Maestro 
(version 9.7) Prepwizard was then run on the aligned coordinates (complex structures) with 
the following settings: find disulfides, fill sidechains, propKa_pH 7.0, OPLS force field 
version 2005, RMSD minimization cutoff of 0.3, cap termini. SiteMAP (version 3.0, 
analysis, Schrödinger, LLC) was then run on only the receptor coordinates, restricting map 
finding to a zero Å box around the 2PQK Bim peptide, with the enclosure setting at 0.4 for 
finding shallow grooves, and with verbose file output.43,44 SiteMAP identified the BH3 
binding groove as the largest site for all structures. Scripts were written in Python (version 
2.6.1) to process the “.smpot” SiteMAP potential output files (lists of coordinates and 
potentials). All points that met the SiteMAP default potential values for hydrophilic (-8 kcal/
mol) and hydrophobic (-0.5 kcal/mol) maps were extracted. The environment around each 
peptide position was analyzed by selecting all map points (donor, acceptor, and hydrophobic 
maps) that were within 6 Å of the Cβ of each position in the Bim peptide in structure 2PQK. 
The intersection between receptors for each type of map at each position was computed by 
counting all points within 1 Å of a point in another receptor’s map. A similarity score was 
computed by summing the intersection counts from the acceptor, donor, and hydrophilic 
maps at all positions.
Clustering
Clustering of proteins by sequence identity, binding profile, or SiteMAP similarity was 
performed in Matlab (version R2012b) with the clustergram function in the Bioinformatics 
toolbox using hierarchical clustering based on correlation. The exception was clustering of 
the peptides (rows in Fig. 3 and 6), which were clustered by Euclidean distance to give 
better ordering according to affinity.
Expression and purification of Bcl-2 proteins
Biotin-acceptor peptide (BAP-tagged) and His6-tagged variants of all eight Bcl-2 homologs 
were made in vector pDW363 (used for analysis of direct binding on the bacterial cell 
surface, and, in the case of M11, for the fluorescence anisotropy experiments).61 Sequence 
encoding MBP in the parent vector was replaced by the Bcl-2 homolog, resulting in a 
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product with the BAP-tag and His6-tag at the N-terminus of the Bcl-2. C-myc-tagged 
versions of all Bcl-2 homologs were in the pSVM vector. Constructs are given in 
Supplementary Table 7.
pDW363 constructs were expressed in BL21 (DE3) pLysS Rosetta cells. 50 mL overnights 
were grown at 37 °C with shaking, and 10 mL of the overnight culture was used to inoculate 
1 L of LB including 100 μg/mL ampicillin, 25 μg/mL chloramphenicol, and 12-15 mg of D-
(+)-biotin. Cells were grown at 37 °C with shaking to an optical density at 600 nm (O.D. 
600) of 0.6 and then induced with 1 mM IPTG for ~5 hours before harvesting. pSVM 
constructs were grown similarly, with 50 μg/mL kanamycin, 25 μg/mL chloramphenicol, 
and no biotin.
Purification of pSVM constructs was performed as follows. 1 L cell pellets were 
resuspended in 25 mL of 5 mM imidazole, 500 mM NaCl, 1 mM DTT, 20 mM Tris pH 8.0, 
and 0.2 mM phenylmethylsulfonyl fluoride (PMSF) protease inhibitor. Cells were sonicated 
ten times for 30 seconds followed by 30 seconds of rest. The supernatant from the 
centrifuged lysis product was filtered through 0.2 μm filters before application to 3 mL of 
Ni-nitrilotriacetic acid agarose resin equilibrated in 20 mM Tris pH 8.0, 500 mM NaCl. 
After the supernatant was applied, the resin was washed 3 times with 8 mL of 20 mM 
imidazole, 500 mM NaCl, 20 mM Tris pH 8.0. The His6-MBP-c-myc-Bcl-2 construct was 
eluted with 8 mL 20 mM Tris pH 8.0, 500 mM NaCl, 300 mM imidazole. At this point, the 
protein in the eluate was quantitated by absorbance at 280 nm and diluted to 1 mg/mL with 
50 mM NaCl, 50 mM Tris pH 8.0, 1 mM DTT, 0.5 mM EDTA, before the addition of TEV 
protease at a ratio of 50 mg Bcl-2 protein:1 mg TEV. The Bcl-2 protein and TEV were 
dialyzed overnight at 4 °C against 1 L of 50 mM NaCl, 50 mM Tris pH 8.0. The dialyzed 
protein was purified by nickel affinity chromatography as before, with the exception that the 
wash buffer did not contain imidazole, to minimize dissociation of His6-MBP and His6-TEV 
from the resin. The flow-through (and if not overly contaminated, the wash) was applied to a 
S75 26/60 size exclusion column equilibrated in 20 mM Tris pH 8.0, 150 mM NaCl, 1% 
glycerol, 1 mM DTT. Purity was verified by SDS-PAGE, and proteins were frozen at −80 
°C in the final buffer. pDW363 constructs were purified similarly, but with no cleavage step, 
and with just one nickel affinity step followed by the size exclusion column.
Binding affinity measurements by fluorescence anisotropy
Library peptides, the Bim BH3 peptide, and Bim BH3 peptide mutants were 23 residues 
long with N-terminal 5/6-fluorescein amidite and C-terminal amidation and were 
synthesized by the MIT Biopolymers Laboratory. The crude synthesis product was verified 
by mass spectrometry to contain predominantly the desired species and then purified by 
HPLC on a C18 column with a linear gradient of acetonitrile in water. Proteome-derived 
BH3 peptides (26-mers, N-fluoresceinated, C-amidated) in Fig. 3 were the same as those 
used by DeBartolo et al.46 Direct fluorescence anisotropy experiments were performed as in 
Foight et al., with a titration of twelve receptor concentrations, with a maximum 
concentration of 1 μM receptor for the library peptide curves and 3 μM for the proteome 
peptide curves.25 C-myc-tagged receptors were used for all Bcl-2 homologs, with the 
exception of M11, for which a BAP and His6-tagged construct was used. All KD values are 
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from averaged data from three replicates done over three days. Data were fit as described for 
direct fluorescence anisotropy experiments in Foight et al., with the upper baseline and KD 
fit, while the lower baseline and concentration of the fluoresceinated peptide were fixed as 
described.25
SPOT arrays
SPOT arrays were synthesized on activated nitrocellulose support using Fmoc protection/
deprotection chemistry by an Intavis AutoSpot robot in the MIT Koch Biopolymers 
Laboratory. The peptides were synthesized with PEG3 (three ethylene glycol units) linkers 
at the carboxy terminus. All peptides were 26 residues long (wild-type Bim sequence 
MRPEIWIAQELLRIGEDEFNAYYARV). Native BH3 peptides in column “X” in Fig. 4, 
top to bottom: Bad, Bid, Bmf, Hrk, Noxa, Bik, Bak, Bax, Bcl-xL, Bcl-w, Bcl-2, Mcl-1, 
Bfl-1, BHRF1, KSBcl-2, with the BH3 residues equivalent to those described for Bim BH3. 
Arrays were processed by first hydrating the membranes in 100% methanol, followed by 
water. Arrays were blocked in blocking buffer (50 mM Tris pH 8.0, 100 mM NaCl, 0.01% 
Triton X-100, 1% BSA) for 20 min. 100 nM c-myc-BHRF1 or KSBcl-2 in blocking buffer 
was applied to the arrays and incubated 1 hr at ~ 23 °C with rocking. Arrays were washed 3 
times with 10 mL blocking buffer before addition of 5 mL blocking buffer + anti-c-myc-Cy3 
(Sigma Aldrich) at 1:100 dilution. Arrays were incubated in the dark for 30 minutes at ~23 
°C with rocking. Finally, the array was washed 3 times with 10 mL blocking buffer, imaged 
on a Typhoon 9400, and analyzed with ImageQuant.
Models used for library design
Illumina sequencing data of a yeast display library sorted for selective binding to KSBcl-2 
but not Mcl-1 and Bcl-xL was used to inform selection of substitutions that are tolerated by 
KSBcl-2 binding.25 Enrichment of residues was computed as the percentage of unique 
sequences with a residue after five rounds of screening minus the percentage of unique 
sequences with that residue in the naïve library. Sequences surviving the selection were 
likely to be moderate to high-affinity KSBcl-2 binders, but not all were selective for 
KSBcl-2. Peptides tested individually in solution bound KSBcl-2 with dissociation constants 
of ~1 nM but also bound to Mcl-1 with similar affinities.25
Position-specific scoring matrices based on SPOT array intensities for KSBcl-2 and BHRF1 
(PSSMSPOT models) were built by computing log10 of each mutant peptide fluorescence 
intensity divided by the average wild-type intensity, as described previously for the human 
Bcl-2 proteins.23,48,49
STATIUM is a statistical potential built to evaluate the fit of a sequence on a particular 
structural template. STATIUM models were built using the STATIUM_sidechain method 
reported by DeBartolo et al., with the exception of Bcl-w, for which the original STATIUM 
method was used.46,48 The template structures used were as follows: a KSBcl-2:Bim BH3 
homology model described above, 2PQK (Mcl-1:Bim BH3)24, 3IO8 (Bcl-xL:Bim 
BH3_L12F)62, 2VM6 (Bfl-1:Bim BH3)63, 2WH6 (BHRF1:Bim BH3)64, and 2XA0 
(Bcl-2:Bax BH3)65. The Bcl-w model was built using template 1ZY366, an NMR-based 
docking model with Bid BH3.
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KSBcl-2 library—To guide library design, all possible point mutants of Bim at positions 
2a-4e were scored with the three models described above, with some positions not having 
data from all models. Substitutions were rated as non-disruptive for KSBcl-2 binding if 
they met at least one of the following criteria:
i. Frequency increase of 1% in the library screening experiment targeting KSBcl-2, or 
present in at least 10% of unique sequences after 5 rounds of screening
ii. PSSMKSBcl-2 score greater than the median score for all mutations across all 
positions
iii. ΔSTATIUM KSBcl-2 (raw Bim score – raw mutant score) greater than the median 
for all mutations across all positions
Substitutions were counted as specific for KSBcl-2 over an alternative receptor if ΔPSSM = 
PSSMKSBcl-2 -PSSMalternative receptor or ΔΔSTATIUM = ΔSTATIUMKSBcl-2 -
ΔSTATIUMalternative receptor was greater than 0.2. As for ΔSTATIUM KSBcl-2, 
ΔSTATIUMalternative receptor was defined as the score for Bim on that receptor minus the 
mutant score on that receptor. The specificity score for each substitution was defined as the 
number of scores that met the aforementioned cutoff (e.g., a specificity score of 10 would be 
given if all ΔPSSM and all ΔΔSTATIUM scores for all 5 human Bcl-2 proteins were greater 
that 0.2). The 0.2 cutoff was chosen because it was close to the average over all receptor 
comparisons of the median ΔPSSM and ΔΔSTATIUM values for all mutations, and seemed 
to represent a reasonable minimal margin of specificity when compared to model scores for 
known specificity mutations.
Libraries were constructed using degenerate codons chosen by a computational optimization 
protocol.67 To guide the selection of a set of degenerate codons to consider at each position, 
residue substitutions were divided into two categories, “preferred” or “required”. 
Substitutions were included in the preferred category if they were non-disruptive by at least 
one out of the three categories previously mentioned and had a specificity score of at least 6 
(or at least 3 for positions with information available from only PSSMSPOT or STATIUM). 
Additionally, some substitutions were included that did not meet this criteria but had large 
ΔPSSM or ΔΔSTATIUM scores for Mcl-1. Required residues included the wild-type 
residues and a subset of the preferred residues that were hand-selected for a high degree of 
specificity, with emphasis placed on specificity against Mcl-1. Degenerate codons selected 
for consideration encoded all of the required residues, and the choices were further narrowed 
by the elimination of any codon that included more trinucleotides than another but encoded 
fewer preferred residues.
Optimization of degenerate codon combinations was performed by integer linear 
programming, as previously described, with a limit on the DNA size of the library set at 1 × 
107.67 At positions where more than one degenerate codon of equal DNA size encoded the 
same number of “preferred” residues, one codon was selected to maximize specificity 
against Mcl-1. Codon options at certain positions were narrowed to encourage the ILP code 
to compose a library in which the majority of positions had a modest number of variants 
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(more than 3). This strategy was employed with the aim of decreasing the likelihood that the 
library sequences would be overly reliant on one or two positions to achieve specificity. 
Several possible library designs arose from different choices of positions to mutate and 
codon choices to include. The final library design was chosen because it contained a large 
number of protein sequences (5.23 × 106), and it had the highest number of sequences that 
scored in a range predicted to have high affinity for KSBcl-2 and weaker binding than Bim 
to Mcl-1 on the PSSMSPOT and STATIUM models. BHRF1 library Design of the BHRF1-
targeted library used the same PSSMSPOT and STATIUM models as described above for the 
cellular receptors. BHRF1 models used to categorize mutations included a PSSMSPOT 
model and STATIUM models built on two templates, 2WH6 (BHRF1:Bim BH3) and 2XPX 
(BHRF1:Bak BH3).64 Preferred residues were defined as all residues that were non-
disruptive by at least one out of three models (i.e., a PSSMBHRF1 or ΔSTATIUMBHRF1 
score above the median across all mutations at all positions). Required residues were 
selected to be non-disruptive and highly specific for BHRF1, with preference given to 
residues that disfavor binding to Mcl-1. A few residues were also included as required 
because PSSMSPOT indicated high affinity binding to BHRF1. Codon selection was 
performed as for the KSBcl-2 library. In selecting the final library, a similar emphasis was 
placed on including 4-8 mutations at as many positions as possible; manual selection of 
codons and adjustment of required residues achieved this goal. The final BHRF1 library had 
a large number of protein sequences (6.72 × 106), as well as large numbers of sequences that 
scored as high for BHRF1 affinity but low for Mcl-1 affinity according to the PSSMSPOT 
and STATIUM models. The final library designs are presented in Supplementary Tables 2 
and 3.
Library construction
The pBAD33-eCPX-FLAG-Bim BH3 construct used for bacterial surface display of the Bim 
variant libraries and the primers used for library construction are shown in Supplementary 
Table 7. The protocol for library assembly was similar to that presented in Getz et al.68 The 
vector into which the library was cloned was pBAD333-eCPX with a FLAG tag included for 
use as an expression control and linkers optimized for Bim BH3 expression and binding. A 
vector containing the non-binding mutant BimL3aD was used as a cloning template to 
prevent background from undigested vector from influencing the screening results. 200 mL 
of this vector expressed in DH5α E. coli was minipreped over 8 Qiagen miniprep columns 
and digested with SfiI according to the NEB protocol for 8 hours. Digested vector was PCR 
purified over an appropriate number of Qiagen PCR purification columns and eluted with 
water. The digested vector was then dephosphorylated with Antarctic phosphatase (1 μL 
phosphatase: 1 μg DNA) at 37 °C for 2 hours, followed by 10 min at 65 °C for deactivation 
of the enzyme. This prevented re-ligation of the original insert back into the vector. This 
protocol yielded 8-10 μg of DNA, which was the amount of vector needed per library.
To prepare the library inserts, a DNA fragment corresponding to the eCPX gene was 
generated by performing PCR with the primers eCPX_rev_library and BimC_fwd_library 
(Supplementary Table 7) on the BimL3aD-eCPX vector. Platinum Taq HiFi polymerase was 
used according to manufacturers instructions. The product was run on an agarose gel using 
GelGreen DNA dye and blue light for visualization to minimize DNA damage. The 
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appropriate band was extracted with a Zymo DNA gel recovery kit. Overlap PCR was then 
performed on this eCPX fragment to add the varied Bim region. For each library, the 
appropriate library primer (1.5 μL at 10 μM) was combined with 1 μL of the eCPX product 
in standard Platinum Taq HiFi conditions. Seven PCR cycles were run with an annealing 
temperature of 54 °C, and then 1 μL of a 12.5 μM mix of the eCPX_rev_library and 
SfiI_fwd primers were added and a further 28 PCR cycles were completed (Supplementary 
Table 7). 15, 50 μL reactions were done per library to obtain sufficient insert DNA. The 
PCR products were purified over Zymo Clean & Concentrate columns and digested with 
SfiI for 4 hours. Digestion reactions were then purified again. This protocol yielded ~7 μg of 
insert DNA for each library.
Digested vector and library insert were ligated at a 5:1 molar ratio of insert:vector, using ~8 
μg vector. An 800 μL reaction volume with standard T4 DNA ligase conditions was used, 
and ligations were performed at 14 °C overnight. A 20 μL control ligation of digested vector 
alone was also performed to allow estimation of vector background. Following ligation, the 
ligase was deactivated at 70 °C for 10 minutes, and the ligation was concentrated over four 
Zymo Clean & Concentrate columns, eluting each column in 12.5 μL DNA elution buffer 
(from the kit). Each ligation aliquot was then desalted for 20 minutes on a Millipore 0.025 
μm filter suspended on an Eppendorf tube of sterile MilliQ water. The ligations were then 
pooled on ice and split between 4, 250 μL aliquots of thawed MC1061 competent E. coli 
cells. MC1061 competent cells were prepared as in Getz et al.68 Each aliquot was 
electroporated in a cold 2 mm BioRad cuvette at 2.5 kV, 50 μF, 100 Ω on a BioRad Gene 
Pulser electroporator, and then immediately rinsed three times with 1 mL warm SOC and 
combined with 7 mL warm SOC and then allowed to recover at 37 °C for 1 hr on a rotator 
wheel. The library was then added to 500 mL LB + 25 μg/mL chloramphenicol + 0.2% w/v 
sterile-filtered glucose in a 2 L flask and grown at 37 °C until an O.D.600 of ~1.5 was 
reached (~7 hours). 400 mL of the library culture was pelleted at 3000 relative centrifugal 
force (rcf) for 15 minutes and re-suspended in 10 mL SOB + 15% v/v sterile glycerol and 
aliquoted and frozen at −80 °C. The number of transformants was 3.9 × 109 for the BHRF1 
library and 1.8 × 109 for the KSBcl-2 library, with vector background estimated at < 
0.001%.
Library Sorting
The general protocol for preparation of library samples for sorting was as follows. A 
quantity of glycerol stock sufficient to oversample the estimated library diversity by at least 
10-fold was used to inoculate 5 mL LB plus 0.2% glucose and 25 μg/mL chloramphenicol 
and grown overnight at 37 °C on a rotator wheel. ~100 μL of overnight culture (or enough to 
maintain library diversity) was pelleted and used to inoculate 5 mL LB plus 25 μg/mL 
chloramphenicol. The culture was then grown to an O.D. 600 of 0.5-0.6 and induced with 
0.04% w/v arabinose for 1 hour. Sufficient cells to oversample the library diversity were 
pelleted at 3000 rcf for 5 minutes and mixed with 100 μL PBS + 0.1% BSA (PBSA) and 100 
μL of an appropriate 2x biotinylated viral Bcl-2 stock. Cells were incubated at room 
temperature with shaking for 1 hour. Cells were pelleted, washed with 200 μL PBSA, 
pelleted again, and then 210 μL of a mix of streptavidin-PE and anti-FLAG-APC (both at a 
1:100 dilution in PBSA) was added. For three-color competition sorts, a two-step antibody 
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labeling process was used. The first incubation was with streptavidin-PE (Molecular 
Probes), anti-FLAG-APC (Perkin Elmer), and rabbit-anti-c-myc (Sigma), and the second 
incubation (after a wash step) was with anti-rabbit-FITC (Sigma). Gates for the three-color 
competition sorts were set to exclude FITC-positive cells and include PE-positive cells. 
Cells were incubated with the labeling reagents for 15 minutes on ice in the dark. The 
pelleting and washing steps were repeated, and cells were resuspended in 1.5 mL PBSA for 
sorting on a BD FACS Aria. Cells were collected in PBSA, which was diluted in SOC after 
sorting and cells were allowed to recover at 37 °C overnight, at which point some cells were 
harvested for glycerol stocks and some were used to inoculate cultures for the next day’s 
sort.
The sorting scheme for the KSBcl-2 library was as follows (summarized in Supplementary 
Fig. 2): sort for binding to 1 μM biotinylated-KSBcl-2 (positive sort; 2.7% of cells collected, 
cells were frozen as a glycerol stock and used to inoculate overnight cultures at a later date), 
sort for cells that do not bind to 500 nM biotinylated-Mcl-1 (negative sort; 7.1% of cells 
collected, the next four sorts after this point were done on consecutive days), positive sort at 
100 nM biotinylated-KSBcl-2 (2.1% collected), negative sort at 300 nM Bfl-1 and Bcl-w 
(21.5% collected), sort for binding to 100 nM biotinylated-KSBcl-2 and in the presence of 
500 nM c-myc-Mcl-1 (competition sort; 3.4% collected), competition sort at 100 nM 
biotinylated-KSBcl-2 and 500 nM c-myc-Mcl-1 (9.9% collected, glycerol stocks were made 
at this point and used to inoculate overnight cultures), competition sort at 100 nM 
biotinylated-KSBcl-2 and 500 nM c-myc-Bcl-w and Bfl-1 (23.7% collected), and finally, 
competition sort at 20 nM biotinylated-KSBcl-2 and 1 μM c-myc-Mcl-1 (0.6% collected). 
Competition sorts were all three-color. As often as possible, sorts were done on consecutive 
days to minimize growth time for the libraries, thereby minimizing potential for the 
occurrence of secondary mutations that imparted growth advantages.
The sorting scheme for the BHRF1 library was as follows: positive sort at 1 μM 
biotinylated-BHRF1 (0.4% of cells collected, cells were frozen as a glycerol stock and used 
to inoculate overnight cultures at a later date), negative sort at 500 nM biotinylated-Mcl-1 
(21.1% of cells collected), positive sort at 100 nM biotinylated-BHRF1 (3.3% collected), 
negative sort at 500 nM biotinylated-Mcl-1 (39.5% collected), competition sort at 100 nM 
biotinylated-BHRF1 and 500 nM c-myc-Mcl-1 (19% collected), competition sort at 100 nM 
biotinylated-BHRF1 and 500 nM c-myc-Mcl-1 (11.3% collected), negative sort at 500 nM 
biotinyalted-Bfl-1 (33.3% collected), and finally, competition sort at 100 nM biotinylated-
BHRF1 and 500 nM c-myc-Mcl-1 and Bfl-1 (5.5% collected). These competition sorts were 
done with no labeling of the c-myc labeled competitor. Clones were conventionally 
sequenced from the sixth and eighth pools of this sorting process. The sorts were largely not 
done on consecutive days, and we noticed that one clone with a growth advantage (clone 
BL8-11) had taken over the library by the final sort. Therefore, to get better diversity for 
Illumina sequencing, we went back to the fourth pool and re-cloned the library into fresh 
vector and fresh MC1061 cells using Gibson assembly, at which point the growth advantage 
disappeared. The BHRF1 library was re-sorted from this point on consecutive days with the 
following scheme (in which competition sorts were three-color): positive sort at 100 nM 
BHRF1 (1.5% collected), competition sort at 100 nM biotinylated-BHRF1 and 400 nM c-
myc-Mcl-1 and Bfl-1 (3.4% collected), negative sort at 500 nM biotinylated-Mcl-1 and 
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Bfl-1 (34.4% collected), competition sort at 100 nM biotinylated-BHRF1 and 500 nM c-
myc-Mcl-1 and Bfl-1 (7.9% collected). We sequenced clones from the sixth and eight pools 
from the first sorting attempt (pools BL6 and BL8). From the second sorting attempt, we 
sequenced 25 clones each from pools BL6’ and BL7’. The accelerated growth clone from 
the first sorting attempt, BL8-11, was not found in the BL6’ and BL7’ pools.
FACS analysis samples were prepared as were samples for sorting, and were analyzed on a 
BD FACS Calibur.
Illumina sequencing and data processing
The KSBcl-2 Bim variant library sorted by yeast surface display was described by Foight et 
al.25 To decrease contamination by peptides that bound the antibody detection reagents, we 
performed two rounds of negative sorting against antibody binding on the fifth library pool. 
The resulting pool and the naïve, unsorted library were prepared for Illumina sampling on a 
Genome Analyzer II, and the data were processed as in DeBartolo et al.48 The information 
from this screen was used in the design of the KSBcl-2 bacterial display library as described 
above.
Bacterial display pools were prepared for Illumina sequencing with a scheme similar to that 
reported by Hietpas et al. for yeast libraries.69 First, 10 mL LB, 0.2% w/v glucose, 25 μg/mL 
chloramphenicol cultures of each library pool were started from glycerol stocks and grown 
overnight at 37 °C. The entire culture was mini prepped with a Qiagen mini prep kit and 
eluted in sterile water. The DNA was diluted to ~50-100 ng/μL, and 1 μL was used for the 
first PCR. The first PCR added an MmeI restriction enzyme site to the 5’ end and a 
universal Illumina sequencing region on the 3’ end. Primers MmeI_fwd and 3prime_rev 
were used in standard Phusion polymerase conditions with no annealing step and 25 cycles 
with a 30 second extension period in each cycle. All primer and adapter sequences are given 
in Supplementary Table 7. PCR products were purified with the Qiagen PCR purification kit 
and eluted in 30 μL sterile water. MmeI digestion was performed with 3.45 pmol DNA:2 μL 
MmeI (NEB) for 1 hour at 37 °C, followed by 20 minutes at 80 °C for enzyme deactivation. 
Double stranded DNA fragments containing Illumina adapters and 5-mer barcodes were 
then ligated onto the 5’ end of the digested DNA. The adapter was double stranded through 
the end of the barcode, leaving a single strand “TC” overhang to anneal with the digestion 
product.
Barcodes were all different by at least 2 bases. 3 barcodes were used for each naïve library, 
2 barcodes each for pools 1, 3, and 5, and 1 barcode each for pools 6, 7, and 8, for a total of 
24 barcodes. Ligations were performed on 30 μL MmeI-digested DNA, with 4 μL 6 μM 
adapter, 4 μL 10x T4 ligase buffer, and 2 μL T4 DNA ligase for 30 minutes at room 
temperature, followed by deactivation of the ligase at 65 °C for 10 minutes. Ligation 
products were run on an agarose gel and ~200 bp bands were extracted with a Zymoclean 
Gel DNA recovery kit and eluted in 15 μL water. The second PCR amplified the ligation 
product and extended the 5’ region to encompass the universal Illumina forward read 
sequencing primer. Standard Phusion polymerase conditions described above were used on 
15 μL of gel-purified ligation product with 0.5 μM finalPCR_fwd and rev primers, with 25 
cycles. PCR products were run an on agarose gel and extracted with the Zymoclean Gel 
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DNA recovery kit and eluted in 30 μL water. Samples were then multiplexed and run in one 
lane on an Illumina Hiseq2000 with paired-end reads of 80 bp using the universal Illumina 
forward sequencing primer and rev_seq primer. A PhiX lane was also run for control.
Illumina sequencing data from the bacterial display library pools were filtered using in-
house scripts written in Matlab and Python. First, the constant positions in the library 
between I2d and R4g were required to match the wild-type DNA sequence exactly, though 
no quality score filtering was imposed upon the constant positions. Second, the variable 
position bases were required to have Illumina quality scores greater than 20 (99% base 
calling accuracy). Finally, sequences were sorted into pools according to their barcodes, 
which had to exactly match a theoretical barcode, though no quality score filtering was 
imposed. Sequence logos were made using Weblogo.70
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• KSBcl-2, BHRF1, and M11 are herpesvirus homologs of anti-apoptotic Bcl-2 
proteins.
• Sequence/structure/binding properties of viral and human Bcl-2 homologs were 
compared.
• SPOT arrays and library screening revealed binding determinants for KSBcl-2 
and BHRF1.
• Peptides were designed to bind viral Bcl-2 proteins in preference to human 
homologs.
• Binding data and peptide reagents inform analysis of viral Bcl-2 function.
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Sequence comparison of 5 human and 3 viral Bcl-2 homologs. (a) Percent sequence identity 
over the entire Bcl-2 domain (without the C-terminal trans-membrane helices or the N-
terminal PEST domain of Mcl-1). (b) Percent sequence identity for residues in the BH3 
binding groove (see Materials and Methods). (c) Sequence alignment used for the sequence 
identity calculations. Dots under residues denote residues in the BH3 binding groove. Motifs 
discussed in the Results section are colored and/or underlined.
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Comparison of the physicochemical characteristics of human and viral Bcl-2 homolog BH3 
binding groove structures using SiteMAP. The intersection score is a measure of similarity 
that takes into account the hydrophobic and hydrogen-bond donor/acceptor characteristics of 
regions of the binding site (see Materials and Methods for details of the metric). The 
structures of eight Bcl-2 homologs were clustered according to the similarity of their 
intersection score profiles. Boxed regions partition receptors or groups of receptors; 
numbers are the average log10(intersection score) over the indicated box and its symmetry-
related box across the diagonal. PDB IDs are given, with the receptor name next to them. All 
mammalian receptors are the human homologs except for several murine Bfl-1 structures 
(“mBfl-1”). The suffix “min” denotes a structure relaxed without the peptide bound. 
Asterisks denote homology models.
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Comparison of BH3 peptide binding profiles for eight Bcl-2 homologs. (a) Interactions with 
functionally validated BH3 peptides, using data from the literature. (b) Interactions with 36 
BH3-like peptides identified from the human proteome. Receptors are clustered based on 
correlation of their binding profiles, and peptides are clustered by Euclidean distance. 
Dissociation constants for the human proteins in panel B were taken from DeBartolo et al. 
Asterisks denote peptide clusters with tighter binding to KSBcl-2 than to Mcl-1. The heat 
map indicates affinity measured by fluorescence anisotropy as log10 (KD in nM), with white 
indicating no detectable binding up to 3000 nM. KD values with 95% confidence intervals 
are given in Supplementary Table 1 for the 36 BH3-like peptides.
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Bim BH3 and point-mutant peptides on SPOT arrays binding to 100 nM BHRF1 or 
KSBcl-2. Each row is labeled with the wild-type Bim residue and the position that was 
varied, and columns are labeled with the substitution. The column labeled “X” included 
peptides with the following BH3 sequences, from top to bottom: Bad, Bid, Bmf, Hrk, Noxa, 
Bik, Bak, Bax, Bcl-xL, Bcl-w, Bcl-2, Mcl-1, Bfl-1, BHRF1, KSBcl-2.
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Bacterial surface display screen for selective binders of KSBcl-2 and BHRF1. (a) The 
libraries were displayed on the N-terminus of eCPX. A FLAG tag was displayed N-terminal 
to the peptide, and peptide expression was detected by an anti-FLAG antibody conjugated to 
APC. Streptavidin-phycoerythrin (SAPE) was used to detect binding of biotinylated Bcl-2 
proteins. (b) Representative FACS plot of wild-type Bim BH3 displayed on the surface of E. 
coli binding to 5 nM biotinylated KSBcl-2. Binding, as reported by PE fluorescence, is 
plotted as a function of expression reported by APC fluorescence. The lower-left quadrant 
includes non-expressing cells. (c) equence logo built from deep sequencing of the naïve and 
eighth (final) library pools, using unique sequences. Heptad positions are indicated, and the 
wild-type Bim residue is given at each position below the logo. Pool 8 sequences included in 
these logos were filtered to include only those sequences also present in pools 6 and 7.
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Enrichment of residues in library sequences versus viral Bcl-2 and Mcl-1 model scores. 
Each point represents a residue and is colored according to enrichment (log2 (frequency in 
final pool/frequency in naïve pool)). The frequencies were calculated from unique sequences 
filtered as described in the Materials and Methods. Residues in the KSBcl-2 library (a, b) 
and BHRF1 library (c, d) are plotted by (a, c) PSSMSPOT scores and (b, d) ΔSTATIUM 
scores. For all models, a score of zero is given for the wild-type residue and scores greater 
than zero indicate tighter binding than wild type.
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Binding of human and viral Bcl-2 homologs to peptides identified from library screening. 
KD values, measured by fluorescence anisotropy, here plotted as log10 (KD in nM), are given 
with 95% confidence intervals in Supplementary Table 6. White indicates no binding up to 
1000 nM. Library peptide sequences are shown to the right, with the heptad register 
indicated above and with varied positions underlined. Bcl-2 protein receptors (in columns) 
were clustered by the correlation of their binding profiles and peptides (in rows) were 
clustered by Euclidean distance.
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Specificity mechanisms employed by library peptides. (a) PSSMSPOT scores for 
substitutions at Bim peptide positions L3a, I3d, and F4a. (b) SiteMAP hydrophobic density 
near position 3a shows extra density (circled) for KSBcl-2, BHRF1, and Mcl-1 (red, green, 
and blue, respectively). Bim with leucine at position 3a (2PQK)24 is in gray, and isoleucine 
at 3a from an Mcl-1-specific peptide (3KZ0)23 is shown in blue. The threonine on helix 5 
and valine on helix 4 from 3KZ0 are also shown in blue. (c) SiteMAP similarity score for 
the region around position 3d, clustered by structure. Black lines divide clusters, and Mcl-1 
structures form a cluster distinct from the other receptors. (d) SiteMAPs for BHRF1 and 
Bfl-1 have significant donor density near the peptide 3g position.
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Specificity mechanisms that disfavor Mcl-1 binding. (a) Natural BH3-like sequences 
showing specificity for binding KSBcl-2 over Mcl-1 have diverse residues at position 4e 
(highlighted), including positively charged residues. (b) Tyrosine at position 4e in an 
Mcl-1:Bim BH3 complex (2PQK, blue:gray).24 (c) Aspartate at position 3f in the same 
Mcl-1:Bim BH3 complex.
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Table 1
Dissociation constants for Bcl-2 homologs binding to mutants of Bim BH3.
KD (nM) a
Bim Bim_R3bS Bim_A2eT Bim_A2eT_E2gG
BHRF1 1.2 ± 0.74
~1.2b 64 ± 37 >1000c
KSBcl-2 1.2 ± 0.79 1.5 ± 0.57 1.8 ± 0.81 1.1 ± 0.49
Mcl-1
<1 c <1 c 0.62 ± 0.55 1.6 ± 0.57
Bfl-1
<1 c 5.2 ± 1.7 32 ± 6.9 260 ± 64
Bcl-w 2.6 ± 2.1 18 ± 5.3 40 ± 9.3 98 ± 35
Bcl-xL 2.6 ± 1.9 3.8 ± 1.4 18 ± 4.9 42 ± 7.1
Bcl-2 1.9 ± 1.3 7.2 ± 3.1 44 ± 3.1 150 ± 27
M11 23 ± 10 210 ± 160 78 ± 19 15 ± 5.3
aValues are given ± 95% confidence intervals.
bAn approximate value is given where the confidence interval was very large, which was a problem for some BHRF1 curves that had a low 
dynamic range for the anisotropy signal.
cValues designated >1000 or <1 nM were too weak or tight to quantify using this assay.
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Table 2
Dissociation constants for Bcl-2 homologs binding to peptides designed for increased specificity against 
Mcl-1.
KD in nM with 95% confidence interval
Peptide Sequence BHRF1 KSBcl-2 Mcl-1
KL6-7 RPQIWIHQGLQRLGDGLNAYYAR
>1000a 1.6 ± 0.45 22 ± 2.8
KL6-7_Y4eK RPQIWIHQGLQRLGDGLNAYKAR
>1000 a 2.9 ± 1.3 ~7800b
KL6-7_D3fA RPQIWIHQGLQRLGAGLNAYYAR
>1000 a 180 ± 80 >5000a
KScomp RPNIWLTQRLQRTGDGLNAYYAR
>1000 a 13 ± 7.3 510 ± 190
BL6-22 RPIIWIGQEISRVGDRENAYYAR 2.2 ± 1.3 1100 ± 860 45 ± 6.1
BL6-22_Y4eK RPIIWIGQEISRVGDRENAYKAR 30 ± 17 750 ± 300 ~2200
aNo binding was observed and the value given is the highest concentration of receptor used for that curve.
bApproximate values had large 95% confidence intervals due to the absence of an upper baseline.
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